Optimistic Buy Rating for Passage Bio Driven by Promising PBFT02 Therapy Potential and Accelerated Approval Pathway

TipRanksDec 2 07:46 ET

Passage Bio Assumed With an Outperform at Wedbush

Yahoo FinanceNov 30 06:55 ET

12 Health Care Stocks Moving In Friday's Pre-Market Session

BenzingaNov 29 16:06 ET

Passage Bio Coverage Assumed by Wedbush at Outperform

Dow JonesNov 29 10:39 ET

Passage Bio Price Target Announced at $4.00/Share by Wedbush

Dow JonesNov 29 10:39 ET · Ratings

Update: Wedbush Raises Price Target on Passage Bio to $4 From $3, Keeps Outperform Rating

MT NewswiresNov 29 09:00 ET · Ratings